Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry

BACKGROUND: Treatment persistence is an important consideration when selecting a therapy for chronic conditions such as rheumatoid arthritis (RA). We assessed the long-term persistence of abatacept or a tumor necrosis factor inhibitor (TNFi) following (1) inadequate response to a conventional synthe...

Descripción completa

Detalles Bibliográficos
Autores principales: Choquette, Denis, Bessette, Louis, Alemao, Evo, Haraoui, Boulos, Postema, Roelien, Raynauld, Jean-Pierre, Coupal, Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555030/
https://www.ncbi.nlm.nih.gov/pubmed/31171024
http://dx.doi.org/10.1186/s13075-019-1917-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555030/
https://www.ncbi.nlm.nih.gov/pubmed/31171024
http://dx.doi.org/10.1186/s13075-019-1917-8

Ejemplares similares